Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 5, 2016, Pages 1300-1306

  Moore, John H ^a   van Opstal, Edward ^a   Kolling, Glynis L ^a   Shin, Jae Hyun ^a   Bogatcheva, Elena ^b   Nikonenko, Boris ^b   Einck, Leo ^b   Phipps, Andrew J ^b   Guerrant, Richard L ^a   Protopopova, Marina ^b   Warren, Cirle Alcantara ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b SEQUELLA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COLISTIN; GENTAMICIN; METRONIDAZOLE; NUCLEOSIDE; SQ641; UNCLASSIFIED DRUG; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CAPURAMYCIN; SQ-641; URIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL SHEDDING; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FECES; HISTOPATHOLOGY; MALE; MOUSE; MURINE MODEL; NONHUMAN; POST TREATMENT SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; STREPTOMYCES GRISEUS; SURVIVAL RATE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL SHEDDING; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; MALE; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URIDINE;

EID: 84965020878     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv479     Document Type: Article

References (20)

1. Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 Suppl 2: S65-70.
2. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
3. Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridiumdifficile infection. Nat Rev Gastroenterol Hepatol 2011; 8: 330-9.
4. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 Suppl 2: 1-26.
5. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
6. Dubuisson T, Bogatcheva E, Krishnan MY et al. In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. J Antimicrob Chemother 2010; 65: 2590-7.
7. Bugg TD, Lloyd AJ, Roper DI. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets 2006; 6: 85-106.
8. Protopopova MN. Capuramycin derivative SQ641 as a new promising lead for treatment of Clostridium difficile infection. In: Abstracts of the Fifty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2014. Abstract F-249. American Society for Microbiology, Washington, DC, USA. http://www.icaaconline. com/php/icaac2014abstracts/data/index.htm.
9. Bogatcheva E, Dubuisson T, Protopopova M et al. Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother 2011; 66: 578-87.
10. Warren CA, van Opstal EJ, Riggins MS et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother 2013; 57: 689-96.
11. Pawlowski SW, Calabrese G, Kolling GL et al. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J Infect Dis 2010; 202: 1708-12.
12. Houser BA, Hattel AL, Jayarao BM. Real-time multiplex polymerase chain reaction assay for rapid detection of Clostridium difficile toxinencoding strains. Foodborne Pathog Dis 2010; 7: 719-26.
13. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
14. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
15. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42.
16. Louie TJ, Emery J, Krulicki Wet al. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
17. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-9.
18. Hedge DD, Strain JD, Heins JR et al. New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag 2008; 4: 949-64.
19. Lopetuso LR, Scaldaferri F, Petito V et al. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog 2013; 5: 23.
20. Vrieze A, Out C, Fuentes S et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014; 60: 824-31.